Nitrospray

Quick links to important sections

Nitrospray

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrospray

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate, GTN)
Form Metered-dose spray (Aerosol solution)
Pharmacological class Organic nitrate; Vasodilator
Common use Acute relief/prophylaxis of episodes related to cardiac demand
Origin Synthetic compound

What Type of Medicine is Nitrospray?

The Nitrospray product is a specialized prescription-only medicine whose primary pharmaceutical identity is defined by its active component, Nitroglycerin (Glyceryl trinitrate or GTN). This single-component preparation belongs to the authoritative pharmacological class of organic nitrates, functioning powerfully as a vasodilator and ultimately as an anti-anginal agent. Pharmacological studies have clinically recognized the efficacy of GTN in reducing myocardial oxygen demand. This confirmed action means the medicine helps to quickly lower the heart's workload during acute episodes. It is distinguished from other nitrates by its intended use for immediate intervention, positioning it as an emergency and rapid-prophylaxis tool, rather than a long-term preventative maintenance therapy.


Composition and Specialized Dosage Form

The product is formulated as a precise solution delivered via a metered-dose spray or aerosol, intended exclusively for sublingual administration beneath the tongue. The high-level composition includes the active Nitroglycerin along with excipients, such as a solvent and propellant base, necessary to ensure solution stability and effective delivery as a fine mist. Nitroglycerin is rapidly absorbed following sublingual administration, supporting its classification as a quick-acting medication. This means the sublingual spray formulation is specifically engineered for speed, allowing the active ingredient to reach the bloodstream promptly and deliver its systemic effect.


General Purpose and Physiological Action Principle

The general purpose of Nitrospray is to swiftly reduce the physical workload on the heart by inducing widespread vasodilation throughout the circulatory system. This mechanism immediately decreases the volume of blood returning to the heart (preload reduction) and simultaneously makes it easier for the heart to eject blood (afterload reduction). By achieving this immediate circulatory easing, the single-component product acts as an effective, rapid onset tool for acute cardiac needs.

Regulatory References

  1. NIH MedlinePlus Drug Information on Nitroglycerin

What side effects are possible with Nitrospray?

Possible Side Effects and Safety Information

The safety profile for Nitrospray (Nitroglycerin sublingual spray) is defined by its strong vasodilator action, with adverse reactions categorized according to standard regulatory frequency tiers found in official prescribing documents.

Frequency-Classified Adverse Reactions

The most frequently documented side effect is headache, which regulatory sources classify as Very Common (occurring in 10% or more of users). Adverse reactions considered Common (1% to 10%) include dizziness, hypotension (low blood pressure), flushing, and tachycardia (increased heart rate). Nausea and vomiting are listed as Uncommon effects.

These effects are grouped by System-Organ Class (SOC), primarily affecting the Nervous System (e.g., headache) and the Vascular System (e.g., hypotension).

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious adverse reactions, notably Severe Hypotension which can potentially lead to Syncope (fainting), and, rarely, paradoxical worsening of angina.

A key safety constraint is the absolute contraindication against the use of this medicine in patients who are also taking Phosphodiesterase type 5 (PDE-5) inhibitors (like sildenafil) or soluble guanylate cyclase stimulators, due to the critical risk of life-threatening hypotension. The spray is also contraindicated in patients with conditions such as severe anemia or increased intracranial pressure.

Exposure and Population Notes

The pattern of adverse effects shows that headache is often more frequent and severe at the start of therapy but may subside with continued use as tolerance develops. Safety notes for special populations advise that older adults may have increased susceptibility to hypotension. Furthermore, the safety and effectiveness of the spray have not been established in pediatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Nitrospray (Glyceryl trinitrate) can lead to severe physiological manifestations documented in regulatory labeling. The clinical presentation is primarily characterized by profound severe hypotension (low blood pressure) and systemic toxicity.

Documented Manifestations and Severe Outcomes

Regulatory sources document symptoms including persistent throbbing headache, vertigo, syncope (fainting), palpitation, and visual disturbance. More severe or life-threatening outcomes include seizure, confusion, coma, and the risk of a fatal outcome. Skin may become cold and cyanotic (bluish), which indicates a serious condition such as Methemoglobinemia. Gastrointestinal distress, including bloody diarrhea, is also noted in overdose cases.

Mandatory Emergency Actions

Immediate emergency medical attention must be sought if overexposure is suspected. Regulators explicitly mandate calling emergency services if the individual has collapsed, is experiencing a seizure, or has trouble breathing. Additionally, prompt medical attention is required if chest pain persists after a total of three metered sprays have been administered within a 15-minute period.

Overdose Management

Treatment is entirely symptomatic and supportive, as no specific antidote is known for nitroglycerin overdose. Regulatory guidance includes procedures such as elevation of the extremities and the administration of therapies to increase central fluid volume. Hospital monitoring, including the assessment of vital signs and ECG, may be required for observation.

Therapeutic Uses of Nitrospray

Main Uses and Benefits of Nitrospray

Nitrospray is a formulation of nitroglycerin, a vasodilator primarily used for the acute management and prevention of chest pain associated with coronary artery disease.

Acute Relief of Angina Pectoris

The primary application of Nitrospray is the rapid relief of an ongoing angina pectoris attack. Angina occurs when the heart muscle does not receive an adequate supply of oxygen-rich blood, often due to the narrowing of the coronary arteries. By relaxing the smooth muscles in the blood vessels, the medication facilitates better blood flow and reduces the workload on the heart, helping to alleviate the pressure, tightness, or pain characteristic of an angina episode.

Prophylactic Use Before Physical Activity

Nitrospray is also utilized as a preventative measure. Individuals with known stable angina may use the spray shortly before engaging in activities that are likely to provoke chest pain, such as:

  • Strenuous physical exercise
  • Exposure to extreme cold weather
  • Situations involving significant emotional stress

Mechanism of Benefit

The therapeutic benefits of Nitrospray are derived from its ability to release nitric oxide, which leads to the relaxation of both peripheral arteries and veins. This process provides two main physiological advantages:

  1. Reduced Preload: By dilating the veins, it decreases the volume of blood returning to the heart, which lowers the pressure within the heart chambers and reduces oxygen demand.
  2. Improved Myocardial Oxygen Supply: By dilating coronary arteries, it can enhance the distribution of blood to areas of the heart muscle that are receiving insufficient oxygen.

Because the spray is administered sublingually (under the tongue), the active ingredient is absorbed directly into the bloodstream through the oral mucosa. This delivery method allows for a rapid onset of action, which is essential during acute cardiac discomfort.

Regulatory References

  1. U.S. National Library of Medicine DailyMed prescribing information

Eligibility and Restrictions for Use

The eligibility for using Nitrospray (nitroglycerin lingual spray) is strictly defined by regulatory authorities and is based on age, concurrent medications, and existing health conditions.

Who Must Not Use Nitrospray (Contraindications)

Nitrospray is contraindicated in patients with the following conditions or circumstances:

  • Concurrent Drug Use: Patients taking Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil) or Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat). This prohibition is absolute due to the risk of severe hypotension.
  • Acute/Severe Conditions: Patients with severe anemia, acute circulatory failure or shock, or conditions causing increased intracranial pressure (e.g., cerebral hemorrhage).
  • Hypersensitivity: Patients with a known allergy to nitroglycerin, other nitrates or nitrites, or any component of the spray.

Conditional Use and Age-Related Rules

Population Group Regulatory Status Restriction/Caution
Pediatric Patients Not Recommended Safety and effectiveness have not been established in children.
Older Adults Established Use Use requires caution due to increased susceptibility to side effects like hypotension.
Pregnancy/Lactation Conditional Use is permitted only if the expected benefit to the mother outweighs any potential risk to the child.

Additional caution is required for patients with Hypertrophic Obstructive Cardiomyopathy or who are volume-depleted or already hypotensive. Use in early myocardial infarction requires careful monitoring.

What should I know about interactions with other medicines?

The official regulatory documentation for Nitrospray (Nitroglycerin) specifies several crucial interaction patterns based on its powerful function as a vasodilator, establishing clear constraints for co-administration.

Contraindicated Combinations and Mandatory Restrictions

The combination of Nitrospray is absolutely contraindicated with certain classes of medicines due to the documented risk of severe, life-threatening hypotension and cardiovascular collapse. These classes include Phosphodiesterase Type 5 (PDE5) Inhibitors (such as Sildenafil, Tadalafil, and Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as Riociguat). Regulatory labels mandate strict timing rules for these prohibited combinations, requiring a minimum separation period—typically 24 to 48 hours—between the administration of the interacting agent and Nitrospray use.

Pharmacodynamic and Exposure Interactions

The product has documented additive hypotensive effects when co-administered with other substances that lower blood pressure. These include other vasodilators, antihypertensive drugs, and certain substances like Tricyclic Antidepressants or alcohol (ethanol).

Specific pharmacologic interactions are also documented:

  • High-dose Aspirin (500 mg to 1000 mg) is reported to significantly increase the maximum plasma concentration of Nitroglycerin.
  • Co-administration with intravenous Heparin may reduce the anticoagulant effect of Heparin.
  • Concomitant use with Alteplase has been documented to decrease the thrombolytic effect of that agent.

This officially documented profile defines the necessary constraints for co-administration as strictly outlined in government labeling.

Mechanism of Action

The mechanism of action for Nitrospray is centered on modulation of the circulatory system's smooth muscle tone, achieved through an enzymatic activation cascade.


Molecular Activation and NO-cGMP Pathway Augmentation

Nitroglycerin (GTN) functions as an enzymatic prodrug, utilizing Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) to release the active signaling molecule Nitric Oxide (NO) within the vascular smooth muscle cells. This NO directly activates soluble Guanylate Cyclase (sGC), increasing the production of cGMP, the core signal for muscle relaxation. This action contributes to the initiation of the downstream vasodilatory response.


Systemic Unloading via Venous Vasodilation

The cGMP-mediated relaxation leads to widespread vasodilation, preferentially affecting the venous (capacitance) vessels. This pooling of blood reduces the volume returning to the heart, a primary physiological change known as preload reduction. By lowering the heart's filling pressure and wall tension, the mechanism decreases the heart's overall Myocardial Oxygen Demand (MVO2).


Mechanistic Constraints and Tolerance Dynamics

The prolonged presence of the drug can lead to nitrate tolerance, a mechanism-dependent constraint where the bioactivating enzyme, ALDH2, is functionally inhibited or depleted. This limits the production of NO, thereby constraining the maximum attainable vasodilation and limiting the full extent of the physiological effect of circulatory unloading under sustained conditions.

Dosage and Administration Information

How to Use Nitrospray

Nitrospray (Nitroglycerin/Glyceryl Trinitrate) is administered via the sublingual route, meaning the metered-dose spray is directed onto or beneath the tongue. This method facilitates rapid systemic absorption, supporting the product’s intended use for immediate, intermittent support, rather than continuous maintenance therapy.


Official Administration Protocol

Usage Entity (High-Level) Standard Instruction
Route of Administration Sublingual only. The spray must not be inhaled.
Unit Dose & Strength 0.4 mg of Nitroglycerin per single spray actuation.
Acute Dosing Schedule Initial dose: one spray. May be repeated every 5 minutes if needed, up to a maximum total of three sprays (1.2 mg) within a 15-minute period.
Prophylactic Use One spray is administered 5 to 10 minutes prior to activities known to precipitate symptoms.

Procedural and Population Requirements

Proper use dictates that the user should be in a sitting position during administration to ensure stable delivery. The spray device requires priming (actuating into the air) before first use, or following periods of prolonged non-use, which ensures the accuracy of the delivered dose. As an acute-use product, there are no missed-dose instructions.

Regarding specific patient populations, prescribing information states that use in pediatric patients is not established. For older adults, standard adult dosing generally applies, although general caution is advised in alignment with the nature of the drug.

These instructions establish the standardized procedural steps and time-based limits that govern the use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitrospray

Nitrospray (sublingual nitroglycerin spray) was studied for its intended short-term action for episodic symptoms. The research record, which includes Randomized Controlled Trials (RCTs) and pharmacokinetic studies, contributes to the broader evidence landscape supporting its regulatory status. The findings describe group patterns observed in the studies, but research does not determine whether an individual will respond similarly.


Evidence for Use in Acute Symptom Relief (Angina Pectoris)

Research has explored the use of Nitrospray to help with outcomes related to physical discomfort experienced during a sudden episode of chest pressure or tightness. Researchers focused on measuring the time to changes in reported symptoms following administration. Studies monitored the spray's absorption speed; pharmacokinetic studies described the measurement of the absorption rate at which the active ingredient enters the bloodstream. Findings related to the timing of measured effects were described, but research provides context and not individual predictions about a patient’s exact response time. What remains uncertain is the lack of long-term outcomes, as research is concentrated on acute effects measured in minutes.


Evidence for Use in Anticipated Symptoms (Prophylaxis)

The spray has also been evaluated in research exploring its use prior to activities anticipated to cause symptoms. These studies often used placebo-controlled RCTs where patients performed standardized exercise. Outcomes monitored were functional measures, such as the patient’s total exercise duration and the time to onset of self-reported angina symptoms. This research described patterns where the use of the spray was studied for its association with outcomes like changes in the time to symptom onset and changes in measured exercise capacity in the observed populations. A key limitation is the short follow-up duration; there is limited information regarding whether the body might develop changes in response over time with frequent use.


Research in Specific Patient Groups and Uncertainties

Studies explored the effect of the spray primarily in adult populations with stable coronary artery disease. Research describing outcomes in children, pregnant populations, or older adults with complex conditions remains limited. The overall research record highlights areas where certainty remains low, including the degree of variability in how quickly the spray is absorbed and cleared from the body, and the general absence of long-term data related to cardiovascular events or mortality.

Key Studies & References

  1. Nitroglycerin Lingual Aerosol Prescribing Information (DailyMed/FDA)

Frequently Asked Questions (FAQ)

Common questions about Nitrospray (FAQ)

Q: How long does the effect of Nitrospray usually last?

A: Official studies indicate that the effects of sublingual nitroglycerin, the active ingredient in Nitrospray, usually begin within two minutes after administration. The anti-anginal effect is generally short-acting. Research has described these effects as no longer present after approximately three hours in observed study populations.

Q: Why do some people feel a headache after using Nitrospray?

A: Headaches are the most frequently reported side effect of the medicine and are related to its main action as a vasodilator, meaning it widens the blood vessels. According to official labeling, these headaches are dose-related, particularly when treatment is first started. Official documents indicate that the frequency and severity of the headaches may lessen as tolerance develops.

Q: Is it normal to feel a burning or tingling under the tongue when using Nitrospray?

A: Patient counseling materials often mention that a tingling or prickling sensation under the tongue may be experienced when using the spray. This sensation is sometimes associated with the sublingual administration route, which is necessary for the medicine to work quickly.

Q: Does Nitrospray affect blood pressure levels?

A: Yes, the medicine is designed to relax the body's blood vessels (vasodilation) to help lower the heart's workload. This process can naturally result in a reduction of blood pressure. Low blood pressure, or hypotension, is listed as a common side effect in official labeling.

Q: How does Nitrospray fit into the overall treatment plan for the condition it treats?

A: Nitrospray is classified as a short-acting agent intended for immediate intervention during sudden episodes of discomfort. It is also used prophylactically, meaning it can be administered a short time before activities known to bring on symptoms. Official guidance notes that it is not intended for use as a continuous, long-term preventative maintenance therapy.

Q: How often do people typically need to use Nitrospray?

A: Regulatory instructions define the maximum limits for use during an acute episode, which is generally no more than three sprays within a 15-minute period. For use before an activity, one spray is administered 5 to 10 minutes prior. The overall typical frequency of use varies between patients and is not standardized in official regulatory labeling beyond these defined limits.

Q: Can Nitrospray interact with common over-the-counter pain relievers?

A: Official regulatory documents specifically highlight an interaction with high-dose aspirin, noting that doses between 500 mg and 1000 mg may increase the concentration of nitroglycerin in the body. Primary drug interaction summaries do not typically list other common over-the-counter pain relievers, but caution is always advised regarding combination use.

Q: Does alcohol consumption affect how Nitrospray works?

A: Yes, the official labeling warns that concurrent use of alcohol (ethanol) can increase the risk of hypotensive effects. This can lead to side effects such as severe dizziness or fainting spells. For this reason, official guidance notes that the combination of alcohol and this medicine is generally not advised.

Q: Is Nitrospray considered a long-term treatment or just for immediate relief?

A: According to official classification, Nitrospray is a short-acting anti-anginal agent. It is intended for rapid therapeutic relief of acute symptoms or for use as a prophylaxis before activity. It is not typically suitable for continuous or prolonged long-term preventative maintenance.

Q: Is Nitrospray the same type of medication as other sprays for the heart?

A: The active ingredient in Nitrospray, nitroglycerin, belongs to a specific group of medicines called organic nitrates. This places it in a distinct pharmacological class. While other sprays or heart medications exist, this classification separates Nitrospray from drugs that use different components and mechanisms of action.

Q: Can Nitrospray cause dizziness or lightheadedness?

A: Yes, dizziness is listed as a common side effect in official documents. Lightheadedness is also documented because these effects are often associated with a drop in blood pressure (hypotension), which the medication is designed to cause.

Q: Are there certain supplements or herbal products that should be avoided with Nitrospray?

A: Patient guidance from authoritative sources notes that certain supplements, such as Hawthorn, Garlic, L-Arginine, and Coenzyme Q10, may have the potential to lower blood pressure. Combining these with Nitrospray may result in excessively low blood pressure.

Q: Is Nitrospray safe for use in older adults (seniors)?

A: The use of this medicine in older adults is established. However, official labeling advises that caution is required in this population. This is due to an increased susceptibility to certain side effects, particularly low blood pressure (hypotension).

Q: Is there a generic version of Nitrospray available?

A: The FDA has approved generic versions of the metered sublingual spray formulation of nitroglycerin. Whether a generic product is currently available depends on the specific brand and market.

Q: Does Nitrospray contain any ingredients that might cause an allergic reaction?

A: Official documents state that the medicine is contraindicated if a person is allergic to the active ingredient (nitroglycerin), other nitrates or nitrites, or any non-active component (excipient) used in the spray formulation.

Q: Are there specific food or beverages that interfere with Nitrospray?

A: Regulatory patient guidance advises caution regarding substances that can lower blood pressure. Official sources note that alcohol and grapefruit juice are often mentioned as substances to be cautious of due to potential interactions.

Q: Are there restrictions on physical activity after using Nitrospray?

A: The medicine is often used as a prophylactic agent 5 to 10 minutes prior to anticipated physical activities to potentially increase tolerance. While the medication is studied for use prior to activity, regulatory guidance notes that sitting down during administration is recommended due to the potential for dizziness or low blood pressure.

Q: What are some common misunderstandings about how to use Nitrospray?

A: Patient instructions often highlight procedural mistakes to avoid. Two common points of emphasis are that the spray must not be swallowed and must not be inhaled. The medicine only works as intended if administered correctly onto or under the tongue for rapid absorption.

Q: Why is this drug in a spray form instead of a pill?

A: Regulatory-supported reviews note that the sublingual spray formulation has advantages over traditional tablets. The spray is specifically designed to provide a faster time to onset of action, ensuring the active ingredient reaches the bloodstream quickly to provide rapid relief.

Q: What happens if I accidentally swallow the spray, is it harmful?

A: Patient instructions clarify that the medicine will not work as intended for acute relief if it is swallowed. This is because the medication relies on rapid absorption through the sublingual tissue to achieve its quick action.

Q: Are there different strengths of Nitrospray available?

A: Official documentation specifies the strength of a single dose as 0.4 mg of nitroglycerin per spray actuation. While the dosage strength per spray is consistent, the product may be available in different canister sizes (e.g., those containing 60 or 200 metered sprays).

Q: What does official guidance say about using Nitrospray for unexpected symptoms?

A: Official guidance addresses the use of the spray for acute episodes, advising that one or two sprays should be administered at the onset of an attack. A dose may be repeated approximately every five minutes, as needed, up to a maximum of three sprays within a 15-minute period.

Q: Can I use Nitrospray if I have kidney problems?

A: Kidney problems are not typically listed as a general contraindication for the medicine. However, regulatory-based patient guidance notes that older adults who experience age-related liver or kidney problems may require caution and a potential adjustment in their dose.

Q: Are there any known issues with Nitrospray and driving or operating machinery?

A: Due to the potential for side effects such as dizziness and lightheadedness, the medication may temporarily affect coordination, reaction time, or judgment. Official patient guidance indicates that individuals should not drive or operate machinery until they are certain how the medicine affects their personal condition.

Q: How does Nitrospray compare to older emergency heart medications?

A: Nitrospray is classified as a short-acting antianginal agent, belonging to the pharmacological class of organic nitrates. This places it in the same class as traditional sublingual nitroglycerin tablets used for acute episodes. This classification distinguishes it from other types of long-term preventative heart medications.

How should Nitrospray be stored and disposed of?

Storage and Disposal Requirements for Nitrospray

The storage and disposal of Nitrospray (Nitroglycerin Lingual Spray) are defined by strict regulatory conditions to maintain product stability.

Official Storage Conditions

Requirement Specific Condition
Temperature Range Store at controlled room temperature (20°C to 25°C), with excursions permitted between 15°C and 30°C.
Protection Must be protected from freezing and kept away from heat to preserve efficacy.
Container Rule Store in the original container; the cap must be kept tightly closed after the first use.

The medication must be stored out of the sight and reach of children.

Disposal and Stability

Nitrospray has a specified in-use stability period: the product must be discarded two months following the primary opening of the foil pouch. Unused or expired medication and the empty canister must be disposed of properly and according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrospray found in:

A-Z Index: